Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Annals of the Rheumatic Diseases

Topics

Medicine

Immunology

Pathology

Dermatology

Internal Medicine

Show all topics

DOI

10.1136/annrheumdis-2013-204741

License

CC-BY-NC

Other Formats

PDF